PMID- 29376995
OWN - NLM
STAT- MEDLINE
DCOM- 20190129
LR  - 20220328
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 117
IP  - 12
DP  - 2017
TI  - [A profile of antidepressive effects of agomelatine and a current view on the 
      mechanism of its action].
PG  - 124-131
LID - 10.17116/jnevro2017117121124-131 [doi]
AB  - Agomelatine is one of the latest antidepressants (melatoninergic agonists) with a 
      new mechanism of action. From the positions of classical monoaminoergic theory, 
      tts mechanism of action is difficult to understand, because the drug increases 
      the levels of monoamines and neurotrophic factors, while not affecting their 
      reuptake and negative feedback, which control neurotransmission level. Besides 
      the effect on suprachiasmatic nucleus, a relevant role in the mechanism of action 
      of agomelatine plays its special functionally selective (with regard to 
      intracellular signaling pathways) interaction with heteromeric complexes of 
      serotonin 5-capital EN, Cyrilliccapital TE, Cyrillic2capital ES, Cyrillic and melatonin MT2 receptors in the hippocampus and cerebral 
      cortex. Agomelatine is competitive to other modern antidepressants in the 
      efficacy assessed by the percentage of complete responders and superior in the 
      total frequency of remissions. Compared to other SSRI antidepressants, 
      agomelatine is more effective for anhedonia. In these cases, agomelatine 
      increases the level of brain-derived neurotrophic factor (BDNF) in the blood of 
      responders.
FAU - Shagiakhmetov, F Sh
AU  - Shagiakhmetov FS
AD  - Serbsky Federal Medical Research Center for Psychiatry and Narcology, Moscow, 
      Russia.
FAU - Anokhin, P K
AU  - Anokhin PK
AD  - Serbsky Federal Medical Research Center for Psychiatry and Narcology, Moscow, 
      Russia.
FAU - Popova, A O
AU  - Popova AO
AD  - Russian University of People's Friendship, Moscow, Russia.
FAU - Shamakina, I Yu
AU  - Shamakina IY
AD  - Serbsky Federal Medical Research Center for Psychiatry and Narcology, Moscow, 
      Russia.
LA  - rus
PT  - Journal Article
PT  - Review
TT  - Profil' antidepressivnykh effektov agomelatina i sovremennyi vzgliad na mekhanizm 
      ego deistviia.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
RN  - 0 (Acetamides)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Receptor, Melatonin, MT2)
RN  - 0 (Receptors, Serotonin, 5-HT2)
RN  - 137R1N49AD (agomelatine)
RN  - 7171WSG8A2 (BDNF protein, human)
SB  - IM
MH  - Acetamides/*pharmacology
MH  - Antidepressive Agents/*pharmacology
MH  - Brain-Derived Neurotrophic Factor/blood/metabolism
MH  - Cerebral Cortex/drug effects/metabolism
MH  - Hippocampus/drug effects/metabolism
MH  - Humans
MH  - Receptor, Melatonin, MT2/*agonists/metabolism
MH  - Receptors, Serotonin, 5-HT2/metabolism
MH  - Suprachiasmatic Nucleus/*drug effects/metabolism
MH  - Synaptic Transmission/drug effects
OTO - NOTNLM
OT  - agomelatine
OT  - anhedonia
OT  - clinical profile
OT  - functional selectivity
OT  - mechanism of action
OT  - pharmacodynamics
OT  - pharmacology
EDAT- 2018/01/30 06:00
MHDA- 2019/01/30 06:00
CRDT- 2018/01/30 06:00
PHST- 2018/01/30 06:00 [entrez]
PHST- 2018/01/30 06:00 [pubmed]
PHST- 2019/01/30 06:00 [medline]
AID - 10.17116/jnevro2017117121124-131 [doi]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(12):124-131. doi: 
      10.17116/jnevro2017117121124-131.